Dyne Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Net Income	-235.94	-168.1	-149.29	-59.44	-14.86	Upgrade
Depreciation & Amortization	2.46	3.35	0.34	0.7	0.27	Upgrade
Share-Based Compensation	19.97	15.18	17.54	6.59	0.03	Upgrade
Other Operating Activities	25.35	-4.07	11.84	5.64	2.73	Upgrade
Operating Cash Flow	-188.16	-153.65	-119.56	-46.51	-11.83	Upgrade
Capital Expenditures	-0.73	-3.07	-3.62	-1.16	-1.65	Upgrade
Change in Investments	84.04	90.27	-134.27	-44.5	0	Upgrade
Investing Cash Flow	83.31	87.2	-137.89	-45.66	-1.65	Upgrade
Share Issuance / Repurchase	54.32	37.39	157.82	246.42	0	Upgrade
Debt Issued / Paid	0	0	0	-0.06	0	Upgrade
Other Financing Activities	-	-	-	134.34	19.99	Upgrade
Financing Cash Flow	54.32	37.39	157.82	380.69	19.99	Upgrade
Net Cash Flow	-50.53	-29.05	-99.63	288.52	6.51	Upgrade
Free Cash Flow	-188.89	-156.71	-123.18	-47.67	-13.48	Upgrade
Free Cash Flow Per Share	-3.17	-3.02	-2.42	-3.31	-5.52	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).